All lobbying filings

FIERCE GOVERNMENT RELATIONS

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) · Trade Organization for Generic Drug Manufacturers and Distributers

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 16, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

JACOBUS VREEBURG New on this filing

Previously held: House Homeland Sec. Cmte.-Staff Asst., Dep. Parl., Parl., Rep. Messer-Leg. Dir., House Rep. Policy Cmte.-Staff Dir., NSC-Staff Officer, Acting Dep. Exec. Sec., Dep. Exec. Sec., House Rep. Conference-Policy Dir., Rep. Stefanik-Policy Dir., USUN-W-Dir.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 7

S 1041
Affordable Prescriptions for Patients Act
S 43
Skinny Labels, Big Savings Act
S 1302
Increasing Transparency in Generic Drug Applications Act
S 1954
Biosimilar Red Tape Elimination Act
S 1414
Expedited Access to Biosimilars Act
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…

Lobbying activity 1

Pharmacy

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, S.1041 - Affordable Prescriptions for Patients Act, S.43 - Skinny Labels - Big Savings Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1954- Biosimilar Red Tape Reduction Act, S.1414 - Expected Access to Biosimilars Act, S.2296 - National Defense Authorization Act for FY 2026, and H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026, Generic Drugs

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.